Artwork

Conteúdo fornecido por KPFA.org - KPFA 94.1 Berkeley, CA. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por KPFA.org - KPFA 94.1 Berkeley, CA ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Corona Calls for 09.03.2024 – Novavax; Mpox

39:24
 
Compartilhar
 

Manage episode 437947646 series 3464906
Conteúdo fornecido por KPFA.org - KPFA 94.1 Berkeley, CA. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por KPFA.org - KPFA 94.1 Berkeley, CA ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Discussed in this episode:

  • The FDA has approved the latest iteration of the Novavax vaccine. Here are the main differences with the MRNA vaccines (Moderna and Pfizer) that had new versions approved slightly earlier:
    • Novavax works by injecting COVID spike proteins into the body, rather than injecting MRNA molecules that tell the body’s cells to manufacture COVID spike proteins for a while. There is some evidence Novavax may carry less risk of side effects on re-vaccination, especially for people who’ve had negative side effects from MRNA vaccination.
    • Because Novavax takes longer to manufacture, this round is calibrated to target a slightly older subvariant of COVID (JN.1) than the MRNA vaccines (KP.2); both are close relatives of the currently dominant subvariant in the the US (KP.3.1.1).
    • After a Novavax booster, antibody production seems to last longer, which may mean protection against severe COVID lasts longer too. (However, antibody production after a Novavax booster also seems to ramp up slower).

  • The WHO has declared a Public Health Emergency of International Concern over mpox.
    • The declaration was driven by a surge of cases in the Democratic Republic of Congo and neighboring countries that appears to be driven by a new variant (Clade 1b).
    • The existing smallpox / mpox vaccine work well to stop the spread of mpox, but the international public health response hasn’t gotten the vaccine everywhere it’s needed.
    • To date, there are no confirmed cases of the new variant in the US, which got its 2022 outbreak under control with a relatively successful vaccination campaign targeting groups at high risk of exposure.

To send us a question in advance of next week’s show, write to: coronacalls@kpfa.org. Tune in live Monday mornings (or Tuesdays when Monday’s a holiday) at 7:30am Pacific at kpfa.org

Podcast music credit: Now Son by Podington Bear, licensed under a Attribution-NonCommercial 3.0 International License.

The post Corona Calls for 09.03.2024 – Novavax; Mpox appeared first on KPFA.

  continue reading

74 episódios

Artwork
iconCompartilhar
 
Manage episode 437947646 series 3464906
Conteúdo fornecido por KPFA.org - KPFA 94.1 Berkeley, CA. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por KPFA.org - KPFA 94.1 Berkeley, CA ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Discussed in this episode:

  • The FDA has approved the latest iteration of the Novavax vaccine. Here are the main differences with the MRNA vaccines (Moderna and Pfizer) that had new versions approved slightly earlier:
    • Novavax works by injecting COVID spike proteins into the body, rather than injecting MRNA molecules that tell the body’s cells to manufacture COVID spike proteins for a while. There is some evidence Novavax may carry less risk of side effects on re-vaccination, especially for people who’ve had negative side effects from MRNA vaccination.
    • Because Novavax takes longer to manufacture, this round is calibrated to target a slightly older subvariant of COVID (JN.1) than the MRNA vaccines (KP.2); both are close relatives of the currently dominant subvariant in the the US (KP.3.1.1).
    • After a Novavax booster, antibody production seems to last longer, which may mean protection against severe COVID lasts longer too. (However, antibody production after a Novavax booster also seems to ramp up slower).

  • The WHO has declared a Public Health Emergency of International Concern over mpox.
    • The declaration was driven by a surge of cases in the Democratic Republic of Congo and neighboring countries that appears to be driven by a new variant (Clade 1b).
    • The existing smallpox / mpox vaccine work well to stop the spread of mpox, but the international public health response hasn’t gotten the vaccine everywhere it’s needed.
    • To date, there are no confirmed cases of the new variant in the US, which got its 2022 outbreak under control with a relatively successful vaccination campaign targeting groups at high risk of exposure.

To send us a question in advance of next week’s show, write to: coronacalls@kpfa.org. Tune in live Monday mornings (or Tuesdays when Monday’s a holiday) at 7:30am Pacific at kpfa.org

Podcast music credit: Now Son by Podington Bear, licensed under a Attribution-NonCommercial 3.0 International License.

The post Corona Calls for 09.03.2024 – Novavax; Mpox appeared first on KPFA.

  continue reading

74 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências